Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 6/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3996605 | 0.88 | MGLL (0.63) | MGLLCYP1A2CYP2D6ALDH1A1HPGD | |
| SCHEMBL18424173 | 0.86 | CYP1A2 (0.73) | MGLLCYP1A2CYP2D6ALDH1A1FAAH | |
| SCHEMBL26042174 | 0.86 | CYP1A2 (0.69) | MGLLCYP1A2CYP2D6ALDH1A1FAAH | |
| SCHEMBL9279984 | 0.86 | KMT2A (0.73) | MGLLCYP1A2CYP2D6ALDH1A1FAAH | |
| SCHEMBL640619 | 0.85 | CYP1A2 (0.76) | MGLLCYP1A2CYP2D6ALDH1A1FAAH | |
| SCHEMBL15932296 | 0.85 | MGLL (0.59) | MGLLCYP1A2CYP2D6ALDH1A1FAAH | |
| SCHEMBL392783 | 0.85 | ALDH1A1 (0.72) | MGLLCYP1A2CYP2D6ALDH1A1FAAH | |
| SCHEMBL1281216 | 0.84 | CYP1A2 (0.60) | MGLLCYP1A2CYP2D6FAAH | |
| SCHEMBL3044836 | 0.84 | MAPT (0.69) | MGLLCYP1A2CYP2D6ALDH1A1FAAH | |
| SCHEMBL1052110 | 0.84 | CYP1A2 (0.60) | MGLLCYP1A2CYP2D6FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118488947-A | Condensed ring substituted six-membered heterocyclic compound, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-9156855-B2 | Regulation of nitric oxide release and biofilm development | Newsouth Innovation Pty Limited (AU) | 2015-10-13 | — | — | US | disclosed |
| US-20140221331-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | UNIVERSITY OF WOLLONGONG (AU) | 2014-08-07 | — | — | US | disclosed |
| EP-1928236-B1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2011-11-23 | — | — | EP | disclosed |
| EP-1928236-B1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2011-11-23 | — | — | EP | disclosed |
| US-7638523-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-12-29 | — | — | US | disclosed |
| US-7638523-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-12-29 | — | — | US | disclosed |
| US-7638523-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-12-29 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| WO-2007038669-A2 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007038669-A2 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2007-04-05 | — | — | WO | disclosed |
| WO-2006081034-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-08-03 | — | — | WO | disclosed |
| EP-0343708-B1 | Avermectin derivatives | MERCK & CO INC (US) | 1995-02-15 | — | — | EP | disclosed |
| EP-0343708-A2 | Avermectin derivatives | MERCK & CO. INC. (US) | 1989-11-29 | — | — | EP | disclosed |
| US-4873224-A | Avermectin derivatives | MERCK & CO., INC. (US) | 1989-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | ABL2, ABL1, PTK2 | MGLL 1901/4885CYP1A2 3884/4885CYP2D6 4305/4885 |
| US-20070191336-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | MGLL 3695/4885CYP1A2 4042/4885CYP2D6 4143/4885 |
| US-20140221331-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | NOS1, NOS2, NOS3 | MGLL 812/4885CYP1A2 1447/4885CYP2D6 3489/4885 |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | KIT, PRKCH, PRKCE | MGLL 2876/4885CYP1A2 3547/4885CYP2D6 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.